PRS30 BUDGET IMPACT ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYÃ') VERSUS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE FROM PUBLIC HEALTH SYSTEM PERSPECTIVE IN CHILE.

PRS30 BUDGET IMPACT ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYÃ') VERSUS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE FROM PUBLIC HEALTH SYSTEM PERSPECTIVE IN CHILE Determine the budget impact of give financial coverage to Trelegy (Fluticasone Furoate/Umeclidinium/Vilanterol in a single-inhaler triple therapy) versus Fluticasone Furoate/Vilanterol (FF/VIL), Umeclidinium/Vilanterol (UMEC/VI) and a multiple inhaler triple therapy which is Fluticasone Propionate 250mg/Salmeterol 25mg and tiotropium 18mcg (FP/SAL + TIO) in patients with COPD moderate to very-severe. The budget impact estimated for Trelegy over the five year versus FF/VIL was -MM$592.7, whilst Trelegy versus UMEC/VI and versus FP/SAL+TIO were estimated in -MM$50.7 and.MM$111.4, respectively. [Extracted from the article]